United Therapeutics Corp Live Stock Price Today, Share Analysis and Chart

Name: United Therapeutics Corp: Is Infosys Ltd. worth buying?
Item: United Therapeutics Corp
Rating: 2.204791625
Author: Trendlyne DVM scores

Momentum Trap

about

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on...

577.63 5.90 (1.03%)

Near 52W High of $607.89

482.9K

XNAS Volume

XNAS 13 Apr, 2026 5:30 PM (EDT)

Low Financial Strength

33.3 / 100

Mid Valuation

39.7 / 100

Technically Moderately Bullish

70.1 / 100

Momentum Trap These stocks have average financials but are currently seeing momentum. Investors should exercise caution in buying these stocks View Similar Embed DVM

644

1Yr Price target upside is 12%

13 analysts

United Therapeutics Corp Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

United Therapeutics Corp Live Stock Price Today, Share Analysis and Chart

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on...

Near 52W High of $607.89

SWOT Analysis

United Therapeutics Corp Live Price Chart